Literature DB >> 3698009

Experimental chemotherapy of human medulloblastoma with classical alkylators.

H S Friedman, O M Colvin, S M Ludeman, S C Schold, V L Boyd, L H Mulhbaier, D D Bigner.   

Abstract

Seven classical alkylators were tested for activity against the continuous human medulloblastoma cell line TE-671 grown in vitro and as s.c. and intracranial xenografts in athymic mice. Drugs tested included melphalan, cyclophosphamide (4-hydroperoxycyclophosphamide in vitro), iphosphamide (4-hydroperoxyiphosphamide in vitro), phenylketocyclo-phosphamide, phenylketoiphosphamide, Asta Z 7557, and thiotriethyl-enephosphoramide. All agents were active, with melphalan demonstrating the most activity in vitro and in vivo. Comparative studies of cyclophosphamide and phenylketocyclophosphamide revealed partition coefficients (log P) of 0.73 and greater than 1.69, respectively, and cyclophosphamide exhibited greater cytotoxic activity in post- (equitoxic) drug administration murine plasma. Hematological toxicity was limited to leukopenia/neutropenia for both of these agents. These studies suggest that the classical alkylators may have a role in the treatment of medulloblastoma and provide a means to further analyze their therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model.

Authors:  L White; K Sterling-Levis; R Fisher; V Tobias
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).

Authors:  Y Okamoto; K Shimizu; K Tamura; Y Miyao; M Yamada; Y Matsui; N Tsuda; H Takimoto; T Hayakawa; H Mogami
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

5.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 6.  Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).

Authors:  H S Friedman; S H Bigner; D D Bigner
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.

Authors:  R L Heideman; E C Douglass; J A Langston; J P Krischer; P C Burger; E H Kovnar; L E Kun; H S Friedman; R Kadota
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.

Authors:  H S Friedman; P C Burger; S H Bigner; J Q Trojanowski; G M Brodeur; X M He; C J Wikstrand; J Kurtzberg; M E Berens; E C Halperin
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

9.  Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.

Authors:  A Ameri; M Poisson; Q M Chen; J Y Delattre
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

10.  Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.

Authors:  M E Dolan; A E Pegg; R C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.